MBX Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
MBX Biosciences, Inc. (MBX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.27 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 556.31K shares, a 103.13% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 715.18K shares, a 21.77% decline year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 287.78K shares, a 372.85% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 286.80K shares.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.76M shares, a 26.38% increase from fiscal 2024.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.39M shares, a 20.41% decline from fiscal 2023.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.75M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 556.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.27M shares 10-Q · filed 2026-08-06 | 1.56M shares derived: sum of 3 quarters · filed 2026-08-06 | 1.85M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 715.18K shares 10-Q · filed 2026-05-07 | 1.00M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.29M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.56M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 287.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 574.58K shares derived: sum of 2 quarters · filed 2026-03-12 | 848.44K shares derived: sum of 3 quarters · filed 2026-03-12 | 1.76M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 286.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 560.66K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.47M shares 10-Q · filed 2025-11-06 | 1.54M shares derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | 273.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.19M shares 10-Q · filed 2025-08-07 | 1.25M shares derived: sum of 3 quarters · filed 2026-03-12 | |
| 2025-03-31 | 914.21K shares 10-Q · filed 2025-05-12 | 975.07K shares derived: sum of 2 quarters · filed 2026-03-12 | ||
| 2024-12-31 | 60.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 1.39M shares 10-K · filed 2026-03-12 | ||
| 2024-09-30 | 1.33M shares 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | 1.75M shares 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |